CoChat

Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial: Pamidronate in liver transplant osteoporosis

Monegal, Ana, Guañabens, Núria, Suárez, María Jesús, Suárez, Francisco, Clemente, Gerardo, García-González, Miguel, De la Mata, Manuel, Serrano, Trinidad, Casafont, Fernando, Torne, Santiago, Barrios, Cesar, Navasa, Miquel · 2009 · Transplant International
Cited by 55

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Rapid bone loss and high rates of fractures occur following liver transplantation. To analyze the effect of intravenous pamidronate on bone loss after liver transplantation. A randomized, double-blind, placebo-controlled study was performed. Seventy-nine patients were randomized to two groups of treatment: the pamidronate group (n = 38) was treated with 90 mg/IV of pamidronate within the first 2 weeks and at 3 months after transplantation; the placebo group (n = 41) received glucose infusions at the same time points. All patients received calcium and vitamin D. Bone mineral density (BMD) at the lumbar spine (L(2)-L(4)) and proximal femur using dual energy X-ray absorptiometry and also spinal X-rays were performed before, and at 6 and 12 months after liver transplantation. Biochemical and hormonal determinations were performed previous to transplantation, at 24 h before and after treatment, as well as at 6 and 12 months after liver transplantation. At 12 months after transplantation, there were significant differences in lumbar BMD changes (6 months: pamidronate 1.6% vs. placebo 0.8%, P = NS; 12 months: pamidronate 2.9% vs. placebo 1%, P < 0.05). Femoral neck BMD decreased in the pamidronate- and placebo groups during the first 6 months (6 months: pamidronate -3.1% vs. placebo -2.9%, P = NS; 12 months: pamidronate -3.2% vs. placebo -3.1%, P = NS). BMD at the trochanter remained stable in the pamidronate group, whilst a reduction was observed in the placebo group at 6 months (6 months: pamidronate -0.7% vs. placebo -3.7%, P < 0.05; 12 months: pamidronate -0.5% vs. placebo -1.2%, P = NS). Moreover, no significant differences in the incidence of fractures, serum parathyroid hormone and serum 25-hydroxyvitamin D values between both groups were found. Pamidronate did not increase the risk of serious adverse events. The results of this study show that 90 mg of intravenous pamidronate within the first 2 weeks and at 3 months following liver transplantation preserve lumbar bone mass during the first year, without significant adverse events. However, pamidronate does not reduce bone loss at the femoral neck and furthermore it does not reduce skeletal fractures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1432-2277.2008.00763.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 55

Metadata

Authors
Monegal, A., Guañabens, N., Suárez, M. J., Suárez, F., Clemente, G., García-González, M., De la Mata, M., Serrano, T., Casafont, F., Torne, S., Barrios, C., & Navasa, M.
Venue
Transplant International
Published
2008-09-15
Volume
22
Issue
2
Pages
198-206
ISSN
0934-0874 (ISSN-L)
OpenAlex
W1507673038
Cited by
55
References
6
FWCI
5.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial: Pamidronate in liver transplant osteoporosis. https://app.cochat.ai/papers/10.1111/j.1432-2277.2008.00763.x
The paper
Monegal, A., Guañabens, N., Suárez, M. J., Suárez, F., Clemente, G., García-González, M., De la Mata, M., Serrano, T., Casafont, F., Torne, S., Barrios, C., & Navasa, M. (2009). Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial: Pamidronate in liver transplant osteoporosis. Transplant International. https://doi.org/10.1111/j.1432-2277.2008.00763.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.